Orchid Cellmark 'Actively Exploring Acquisitions' as ‘06 Reorg Gets Traction | GenomeWeb
NEW YORK (GenomeWeb News) — Orchid Cellmark is “actively exploring acquisition opportunities" as a reorganization begun in 2006 gains traction, CEO Thomas Bologna said in a statement.
 
Bologna made the remark in a statement disclosing the company’s fourth-quarter financial report, which included a 1.6-percent rise in revenue, a 25-percent decline in R&D spending, and a profit.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.